In HCT 116 (colorectal), K562 (chronic myeloid leukemia), KB (oral), and T47D (breast) cancer cells lines, it has been shown that 48 h of DET treatment (7.46, 4.02, 3.35, and 1.86 μg/mL, respectively), increased the G2/M phase DNA proportion with a concomitant decrease in G1 and S phase DNA content, indicating a G2/M phase arrest by increasing p21 expression and decreasing cyclin B1 and cdc2 expression. Here, CDK1 is linked to cancer.